The clinical study with the product candidate APN401 for the treatment of solid tumors was started yesterday and is to include a total of around 60 patients at several study centers in Austria.
The principle of cell therapy with APN401 targets the patient’s own immune cells. These are modified in such a way that they can recognize and destroy cancer cells without being permanently genetically modified.
Own cells against cancer
For the treatment, the patient’s own peripheral blood cells are taken, specifically modified outside the body using RNAi technology, and then returned to the patient. For this purpose, Apeiron uses a specially developed system that enables an automated process from processing the cells to reinfusion within just one day, according to the company’s broadcast.
“Your own immune system is the most effective weapon against a tumor disease and offers many advantages over conventional therapeutic approaches such as chemotherapy,” says Romana Gugenberger, Board Member for Research and Development at Apeiron Biologics.
And CEO Peter Llewellyn-Davies added: “APN401 could give seriously ill patients with previously difficult to treat cancers new individualized therapy options and thus new hope.”
I am Pierce Boyd, a driven and ambitious professional working in the news industry. I have been writing for 24 Hours Worlds for over five years, specializing in sports section coverage. During my tenure at the publication, I have built an impressive portfolio of articles that has earned me a reputation as an experienced journalist and content creator.
